company background image
OSL logo

OncoSil Medical CHIA:OSL Stock Report

Last Price

AU$0.006

Market Cap

AU$31.5m

7D

-14.3%

1Y

-33.3%

Updated

22 Dec, 2024

Data

Company Financials

OSL Stock Overview

A medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe. More details

OSL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

OncoSil Medical Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for OncoSil Medical
Historical stock prices
Current Share PriceAU$0.006
52 Week HighAU$0.015
52 Week LowAU$0.004
Beta0.94
1 Month Change-14.29%
3 Month Change-53.85%
1 Year Change-33.33%
3 Year Change-86.36%
5 Year Change-96.47%
Change since IPO-93.10%

Recent News & Updates

Recent updates

Shareholder Returns

OSLAU Life SciencesAU Market
7D-14.3%1.1%-2.7%
1Y-33.3%13.8%6.5%

Return vs Industry: OSL underperformed the Australian Life Sciences industry which returned 13.8% over the past year.

Return vs Market: OSL underperformed the Australian Market which returned 6.5% over the past year.

Price Volatility

Is OSL's price volatile compared to industry and market?
OSL volatility
OSL Average Weekly Movement14.9%
Life Sciences Industry Average Movement8.9%
Market Average Movement8.0%
10% most volatile stocks in AU Market16.8%
10% least volatile stocks in AU Market3.1%

Stable Share Price: OSL's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: OSL's weekly volatility has decreased from 22% to 15% over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2005n/aNigel Langewww.oncosil.com

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe. Its lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

OncoSil Medical Limited Fundamentals Summary

How do OncoSil Medical's earnings and revenue compare to its market cap?
OSL fundamental statistics
Market capAU$31.48m
Earnings (TTM)-AU$11.91m
Revenue (TTM)AU$1.57m

20.1x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OSL income statement (TTM)
RevenueAU$1.57m
Cost of RevenueAU$1.51m
Gross ProfitAU$55.63k
Other ExpensesAU$11.97m
Earnings-AU$11.91m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0026
Gross Margin3.55%
Net Profit Margin-761.07%
Debt/Equity Ratio0%

How did OSL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OncoSil Medical Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Thomas DuthyTaylor Collison Limited
Shane StoreyWilsons Advisory and Stockbroking Ltd.